| pubmed-article:17226962 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17226962 | lifeskim:mentions | umls-concept:C0596901 | lld:lifeskim |
| pubmed-article:17226962 | lifeskim:mentions | umls-concept:C1414313 | lld:lifeskim |
| pubmed-article:17226962 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:17226962 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:17226962 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:17226962 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17226962 | pubmed:dateCreated | 2007-1-17 | lld:pubmed |
| pubmed-article:17226962 | pubmed:abstractText | The objective of the present study was to construct epidermal growth factor receptor (EGFR) targeting cetuximab-immunoliposomes (ILs) for targeted delivery of boron compounds to EGFR(+) glioma cells for neutron capture therapy. The ILs were synthesized by using a novel cholesterol-based membrane anchor, maleimido-PEG-cholesterol (Mal-PEG-Chol), to incorporate cetuximab into liposomes by either surface conjugation or a post-insertion method. For post-insertion, the transfer efficiency of MAb conjugates from micelles to liposome was examined at varying temperatures, mPEG2000-DSPE ratios, and micelle-to-liposome lipid ratios. Following this, the cetuximab-ILs were evaluated for targeted delivery of the encapsulated boron anion, dodecahydro-closo-dodecaborate (2-) (B12H122-), to human EGFR gene transfected F98EGFR glioma cells as potential delivery agents for boron neutron capture therapy (BNCT). In addition, cellular uptake of cetuximab-ILs, encapsulating a fluorescence dye, was analyzed by confocal fluorescence microscopy and flow cytometry, and boron content was quantified by ICP-MS. Much greater ( approximately 8-fold) cellular uptake of boron was obtained using cetuximab-ILs in EGFR(+) F98EGFR compared with nontargeted human IgG-ILs. On the basis of these observations, we have concluded that cholesterol can serve as an effective anchor for MAb in liposomes, and cetuximab-ILs are potentially useful delivery vehicles for BNCT of gliomas. | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17226962 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17226962 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17226962 | pubmed:issn | 1043-1802 | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:GranGG | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:BarthRolf FRF | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:TjarksWernerW | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:LeeRobert JRJ | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:PanXiaogangX | lld:pubmed |
| pubmed-article:17226962 | pubmed:author | pubmed-author:YangWeiliangW | lld:pubmed |
| pubmed-article:17226962 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17226962 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:17226962 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17226962 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17226962 | pubmed:pagination | 101-8 | lld:pubmed |
| pubmed-article:17226962 | pubmed:dateRevised | 2011-9-26 | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:meshHeading | pubmed-meshheading:17226962... | lld:pubmed |
| pubmed-article:17226962 | pubmed:articleTitle | Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. | lld:pubmed |
| pubmed-article:17226962 | pubmed:affiliation | Division of Pharmaceutics, College of Pharmacy, NSF Nanoscale Science and Engineering Center (NSEC), Center for Affordable Nanoengineering of Polymeric Biomedical Devices (CANPBD), The Ohio State University, Columbus, Ohio 43210, USA. | lld:pubmed |
| pubmed-article:17226962 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17226962 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:17226962 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17226962 | lld:pubmed |
